
|Slideshows|June 28, 2018
ADA 2018: CV Benefits of SGLT-2 Inhibitors
Author(s)Kenneth J. Bender, PharmD, MA
Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
ACOG Releases New Guidance on HIV Screening and Prevention
2
2026 Dyslipidemia Guideline Expands Statin Eligibility to 21.5 Million More US Adults
3
From Amyloid Clearance to Daytime Function: Why Sleep Quality Matters for Brain Health
4






























































































































































